WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac BioPharma") is an innovative biopharmaceutical enterprise integrating vaccine R&D, production and sales. With the continuous investment and support of many powerful shareholders -- CICC Capital, Shanghai Pharma, Haier Biomedical and so on, WestVac BioPharma has been successfully selected into the list of unicorn companies for two consecutive years from 2021 to 2022.
In terms of production, quality, operations management, etc., WestVac Biopharma has introduced top talents from well-known domestic and international vaccine companies, established a complete production and quality management system, has more than 300 employees to ensure mass production of vaccines can proceed smoothly.
WestVac Biopharma has a mature insect cell expression platform, mRNA vaccine platform, novel adjuvant platform, bacterial vaccine platform, tumor vaccine and immunotherapy platform, with more than 20 pipelines including COVID-19 vaccine, multivalent influenza vaccine, herpes virus vaccine, tumor immunity preparations.
Phase III clinical trials of the first generation Recombinant COVID-19 Vaccine (Sf9 cells)-Coviccine, have been rolled out globally in multiple countries, with nearly 40,000 subjects enrolled and vaccinated. The clinical trials in Japan for marketing purpose have been concluded, which is the first Chinese COVID-19 vaccine that entered clinical trials in a developed country. Study results show that the vaccine has good safety and immunogenicity with protection against Omicron subvariants of COVID-19 as high as 70.95%. It is one of the most effective vaccines against symptomatic Omicron subvariants globally so far, fully demonstrating the advantages and characteristics of the recombinant protein vaccine technology route.
Meanwhile, WestVac BioPharma has achieved significant progress in the Recombinant COVID-19 Vaccine (Sf9 cells) with a high titer of neutralizing antibody against COVID-19 variant strains including Omicron and Delta. Targeting the S-RBD protein of the COVID-19 variant strain, the subunit vaccine antigen is precisely designed based on the structure, which can self-assemble into stable protein particles. Mass production of the vaccine adopts internationally advanced insect cell production technology. The pre-clinical studies have been concluded, indicating that the vaccine is of good safety and tolerance and able to induce very high titers of neutralizing antibodies against variant strains such as Omicron and Delta in multiple species.
WestVac Biopharma has built a production base with an annual production capacity of 600 million doses in Chengdu Tianfu International Bio-town, has completed the construction and verification of GMP production workshop, and obtained the "Drug Manufacturing License". In addition, Guangzhou production base with an annual capacity of 500 million doses is also under construction. WestVac Biopharma has established a sound communication mechanism with many international organizations such as the World Health Organization (WHO), Bill & Melinda Gates Foundation, PATH, The Coalition for Epidemic Preparedness Innovations (CEPI).
In the future, WestVac Biopharma will grow into a world leading vaccine and immunotherapy platform in line with the corporate philosophy of "We Initiate Science & Technology Value, Always for Caring", seek innovation in the prevention and overcome of human diseases, bring innovative vaccines and immunotherapies from China to the world for the benefit of mankind.
